Dr. Patnaik on Challenges With Sequencing Therapies in mCRPC

Akash Patnaik, MD, PhD
Published: Thursday, Aug 11, 2016


Akash Patnaik, MD, PhD, assistant professor of Medicine at the University of Chicago Medicine, discusses the challenges with sequencing available agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

There have been several agents that have been FDA-approved for mCRPC since 2009, Patnaik says, explaining that the landscape has evolved significantly in the last 7 years. However, oncologists are unsure on how to best sequence these therapies or even possibly combine them. Ongoing clinical trials may be able to answer such questions.

Currently, the therapies available are typically sequenced based on access, availability, and reimbursement potential, which all need to be individualized for a given patient.
SELECTED
LANGUAGE

Akash Patnaik, MD, PhD, assistant professor of Medicine at the University of Chicago Medicine, discusses the challenges with sequencing available agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

There have been several agents that have been FDA-approved for mCRPC since 2009, Patnaik says, explaining that the landscape has evolved significantly in the last 7 years. However, oncologists are unsure on how to best sequence these therapies or even possibly combine them. Ongoing clinical trials may be able to answer such questions.

Currently, the therapies available are typically sequenced based on access, availability, and reimbursement potential, which all need to be individualized for a given patient.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x